ArticleBMC gastroenterology2025
Comparative trends in pancreatic cancer burden and risk factors in the USA and China (1990-2021): insights from GBD analysis.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer (PC) remains a lethal malignancy with rising global incidence, yet disparities in risk profiles between high-income and transitioning economies are poorly characterized. This study compared PC burden trends and attributable risk factors in China and the USA (1990–2021), offering evidence for region-specific prevention.
methodswe calculated age-standardized incidence/mortality rates (ASIR/ASMR), with all estimates reported as point values and 95% uncertainty intervals (UI). Joinpoint regression identified temporal inflection points, and future burdens (2022–2030) were projected via ARIMA modeling. Decomposition analysis quantified contributions of aging, population growth, and epidemiology.
resultsFrom 1990 to 2021, China’s ASIR increased from 4.54 (95%UI: 3.84–5.29) to 5.64 (95%UI: 4.52–6.84), representing a 24.2% rise (AAPC: 0.72%, 95%CI: 0.50–0.94), while the USA increased from 9.33 (95%UI: 8.77–9.65) to 10.33 (95%UI: 9.53–10.80) (+ 10.7%, AAPC: 0.33%, 95%CI: 0.14–0.52), driven predominantly by aging (55.7% contribution). Smoking accounted for 28.33% (95%UI: 26.03–30.62) of male PC deaths in China, while metabolic risks dominated in the USA, with 36.41% (95%UI: 4.77–63.81) attributed to high fasting plasma glucose. According to ARIMA forecasts, China’s ASIR is projected to increase to 5.95 (95%CI: 5.61–6.30) per 100,000 by 2030, which indicates a reduction in the disparity between China and the USA, where the ASIR is expected to reach 10.62 (95%CI: 10.20–11.04) per 100,000.
conclusionDivergent risk drivers necessitate tailored policies: tobacco taxation and smoke-free legislation in China; obesity prevention and glycemic control in the USA. Global prioritization of early detection technologies is critical to mitigate projected mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.